Activation of complement system by mannan pathway and Mbl2 genotypes in patients with type 2 diabetes and nephropathy

  • Tjaša Cerar Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Zaloška 4, 1000 Ljubljana, Slovenia
  • Draženka Pongrac Barlovič Clinical Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Zaloška 7, 1000 Ljubljana, Slovenia
  • Anže Zorin Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Zaloška 4, 1000 Ljubljana, Slovenia
  • Nadan Gregorič Clinical Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Zaloška 7, 1000 Ljubljana, Slovenia
  • Vladimir Kotnik Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Zaloška 4, 1000 Ljubljana, Slovenia
Keywords: nephropathy, diabetes, complement, mannan binding lectin

Abstract

To add new evidence that complement activation by the mannan (lectin) pathway is involved in the pathogenesis of nephropathy in patients with type 2 diabetes, we collected blood and urine samples from 20 patients with type 2 diabetes and nephropathy and 20 apparently healthy individuals from the general population. We performed tests for complement activation analysis (CH50, APH50, C3, C4, C3d/dg, C4d, SC5b-9, MBL and genotyping of Mbl2 gene) in blood and (C3d/dg, C4d,  MBL, and SC5b-9) in urine. We found significant signs of complement activation in patients with type 2 diabetes and nephropathy in blood and in urine. We also observed significant genetic differences between healthy individuals and patients with type 2 diabetes and nephropathy concerning the Mbl2 gene. Healthy individuals were apparently more heterogeneous (45 % A0 type) in presentation of the structural Mbl2 genotype, giving intermediate and low levels of MBL protein, compared to patients with type 2 diabetes and nephropathy, who had a very homogenous Mbl2 genome (75 % AA type) giving a high level of MBL production. From our data we can conclude that patients with type 2 diabetes and nephropathy presents more frequently with Mbl2 gene polymorphism giving high production of the MBL protein, what is very likely connected with acquired renal injury.

Downloads

Download data is not yet available.

References

Mather A, Pollock C. Glucose handling by the kidney. Kidney Int Suppl 2011(120):S1-6.

Mellbin LG, Hamsten A, Malmberg K, Steffensen R, Ryden L, Ohrvik J et al. Mannose-binding lectin genotype and phenotype in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Diabetes Care 2012;33: 2451-6.

Elawa G, AoudAllah AM, Hasaneen AE, El-Hammady AM. The predictive value of serum mannan-binding lectin levels for diabetic control and renal complications in type 2 diabetic patients. Saudi Med J 2011;32:784-90.

Hovind P, Hansen TK, Tarnow L, Thiel S, Steffensen R, Flyvbjerg A, et al. Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study. Diabetes 2005;54: 1523-7.

Garred P, Larsen F, Seyfarth J, Fujita R, Madsen HO. Mannose-binding lectin and its genetic variants. Genes and Immunity 2006;7: 85-94.

Fortpied J, Vertommen D, Van Schaftingen E. Binding of mannose-binding lectin to fructosamines: a potential link between hyperglycaemia and complement activation in diabetes. Diabetes Metab Res Rev 2010;26: 254-60.

Pitkanen E. Mannose, mannitol, fructose and 1,5-anhydroglucitol concentrations measured by gas chromatography/mass spectrometry in blood plasma of diabetic patients. Clin Chim Acta 1996;251: 91-103.

Pitkanen E. Proteinuria and plasma hexosugars in early-stage glomerulonephritis. Clin Nephrol 1996;45: 226-9.

Sato T, Katayama K, Arai T, Sako T, Tazaki H. Simultaneous determination of serum mannose and glucose concentrations in dog serum using high performance liquid chromatography. Res Vet Sci 2008;84: 26-9.

Mori A, Sato T, Lee P, Furuuchi M, Tazaki H, Katayama K, et al. Clinical significance of plasma mannose concentrations in healthy and diabetic dogs. Vet Res Commun 2009;33: 439-51.

Kotnik V, Premzl A, Skoberne M, Malovrh T, Kveder R, Kaplan-Pavlovcic S, et al. Demonstration of apoptosis-associated cleavage products of DNA, complement activation products SC5b-9 and C3d/dg, and immune complexes CIC-C3d, CIC-IgA, and CIC-IgG in the urine of patients with membranous glomerulonephritis. Croat Med J 2003;44: 707-11.

Mayer M, editor. Complement and complement fixation. Springfield (IL): Charles C. Thomas Publisher; 1961. p. 133-240.

Joiner KA, Hawiger A, Gelfand J. A study of optimal reaction conditions for an assay of the human althernative complement pathway. Am J Clin Pathol 1983;79:65-72.

Accardo-Palumbo A, Triolo G, Casiglia D, Salli L, Giardina E. Two-site ELISA for quantification of the terminal C5b-9 complement complex in plasma. I Immunol Methods 1993;163:169-72.

Brandslund I, Siersted H, Svehag S, Teisner B. Double-decker rocket immunoelectrophoresis for direct quantitation of complemnt C3 split products with C3d specificities in plasma. J Immunol Methods 1981;44:63-71.

Saraheimo MT, Forsblom C, Hansen TK, Teppo AM, Fagerudd J, Pettersson-Fernholm K, et al. Increased levels of mannan-binding lectin (MBL) in Type 1 diabetic patients with incipient and overt nephropathy. Diabetologia 2004;47:A389-A389.

Endo M, Ohi H, Ohsawa I, Fujita T, Matsushita M, Fujita T. Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrology Dialysis Transplantation 1998;13: 1984-90.

Lhotta K, Wurzner R, Konig P. Glomerular deposition of mannose-binding lectin in human glomerulonephritis. Nephrology Dialysis Transplantation 1999;14: 881-6.

Ohsawa I, Ishii M, Ohi H, Tomino Y. Pathological Scenario with the Mannose-Binding Lectin in Patients with IgA Nephropathy. Journal of Biomedicine and Biotechnology 2012;2012:476739.

Ma R, Cui Z, Liao YH, Zhao MH. Complement Activation Contributes to the Injury and Outcome of Kidney in Human Anti-glomerular Basement Membrane Disease. J Clin Immunol 2012:1573-2592

Mellbin LG MK, Rydén L, Wedel H, Vestberg D, Lind M. The relationship between glycaemic variability and cardiovascular complications in patients with acute myocardial infarction and type 2 diabetes: a report from the DIGAMI 2 trial. Eur Heart J 2013;34: 374-9.

Schafranski MD, Stier A, Nisihara R, Messias-Reason IJT. Significantly increased levels of mannose-binding lectin (MBL) in rheumatic heart disease: a beneficial role for MBL deficiency. Clinical and Experimental Immunology 2004;138: 521-5.

Kotnik V, Zaletel J. Complement in diabetic nephropathy. Molecular Immunology 2011;48: 1719-20.

Muller YL, Hanson RL, Bian L, Mack J, Shi X, Pakyz R, et al. Functional variants in MBL2 are associated with type 2 diabetes and pre-diabetes traits in Pima Indians and the old order Amish. Diabetes 2010;59: 2080-5.

Kaunisto MA, Sjolind L, Sallinen R, Pettersson-Fernholm K, Saraheimo M, Frojdo S, et al. Elevated MBL concentrations are not an indication of association between the MBL2 gene and type 1 diabetes or diabetic nephropathy. Diabetes 2009;58: 1710-4.

Vaidya VS, Niewczas MA, Ficociello LH, Johnson AC, Collings FB, Warram JH, et al. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-beta-D-glucosaminidase. Kidney Int 2011;79:464-70.

Matica J, Rački Čargonja V, S. D. Učunak trajanja šečerne bolesti tipa 1 na aktivnost N-acetil-beta-D glucosaminidaze u mokraći djece i adolescenata. Biochem Med 2005;16: 50-6.

Kavukcu S, Soylu A, Turkmen M. The clinical value of urinary N-acetyl-beta-D-glucosaminidase levels in childhood age group. Acta Medica Okayama 2002;56: 7-11.

Siezenga MA, Shaw PKC, Daha MR, Rabelink TJ, Berger SP. Low Mannose-Binding Lectin (MBL) genotype is associated with future cardiovascular events in type 2 diabetic South Asians. A prospective cohort study. Cardiovascular Diabetology 2011. V tisku.

Hansen TK, Gall MA, Tarnow L, Thiel S, Stehouwer CD, Schalkwijk CG et al. Mannose-binding lectin and mortality in type 2 diabetes. Arch Intern Med 2006;166: 2007-13.

Jowett JB. Interplay of genetic and environmental factors: Innate immunity genetic polymorphisms in MBL2 affect endothelial dysfunction and risk of atherosclerosis. Atherosclerosis 2010;208: 32-3.

Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000;355: 773-8.

Pavlov VI, La Bonte LR, Baldwin WM, Markiewski MM, Lambris JD, Stahl GL. Absence of mannose-binding lectin prevents hyperglycemic cardiovascular complications. Am J Pathol 2012;180: 104-12.

Wyatt R, Julian B. Activation of complement in Iga nepropathy. Am J Kidney Dis 1988;12: 437-42.

Walsh MC, Bourcier T, Takahashi K, Shi L, Busche MN, Rother RP, et al. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. Journal of Immunology 2005;175: 541-6.

Busche MN, Walsh MC, McMullen ME, Guikema BJ, Stahl GL. Mannose-binding lectin plays a critical role in myocardial ischaemia and reperfusion injury in a mouse model of diabetes. Diabetologia 2008;51: 1544-51.

Garred P, Larsen F, Madsen HO, Koch C. Mannose-binding lectin deficiency--revisited. Mol Immunol 2003;40: 73-84.

Steffensen R, Thiel S, Varming K, Jersild C, Jensenius JC. Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. J Immunol Methods 2000;241: :33-42.

Trendelenburg M, Theroux P, Stebbins A, Granger C, Armstrong P, Pfisterer M. Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J 2010;31: 1181-7.

Rossing P, de Zeeuw D. Need for better diabetes treatment for improved renal outcome. Kidney Int Suppl 2011;79: S28-32.

Published
2014-11-03
How to Cite
1.
Cerar T, Pongrac Barlovič D, Zorin A, Gregorič N, Kotnik V. Activation of complement system by mannan pathway and Mbl2 genotypes in patients with type 2 diabetes and nephropathy. TEST ZdravVestn [Internet]. 3Nov.2014 [cited 5May2024];83(10). Available from: http://vestnik-dev.szd.si/index.php/ZdravVest/article/view/103
Issue
Vol 83 No 10 (2014): October
Section
Original article


The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.

The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory

The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.

The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.

The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.